Human male germ cell tumors (GCTs) result from malignant transformation of premeiotic or early meiotic germ cells and exhibit embryonal-like differentiation of the three germinal layers. The genetic basis of orign and expression of differentiated phenotypes by GCTs are poorly understood. Our recent cytogenetic analysis of a large series of GCTs has shown that two chromosome 12 abnormalities, an isochromosome for the short arm [i(12p)J and deletions in the long arm [del(12q)], characterize these tumors, which led us to suggest that the deletions represent loss of one or more candidate tumor suppressor genes whose products regulate the normal proliferation of the spermatogonial stem cells. We undertook a molecular mapping of the deletions by comparing germ-line and tumor genotypes of eight polymorphic loci in paired normal/tumor DNA samples from 45 GCT patients. Analysis of loss of constitutional heterozygosity at these loci revealed two regions offrequent loss (>40%), one at 12q13 and the other at 12q22, identifying the sites of the postulated tumor suppressor genes. One tumor (no. 143A) exhibited a homozygous deletion of a region of 12q22, which included the MGF gene. The KIT and MGF genes have been shown to play key roles in embryonal and postnatal development of germ cells; therefore, we evaluated their expression by Northern blot analysis in a panel of three GCT cell lines and 24 fresh GCT biopsies. Deregulated expression of MGF and KIT, which was discordant between seminomatous and nonseminomatous lesions, was observed.
Human male germ cell tumors (GCTs) make up a unique biological system for the study of malignancy and differentiation. They exhibit, to varying degrees, embryonal-like differentiation of the three germinal layers (1) . The genetic basis of malignant transformation and expression of differentiated phenotypes by the transformed cells are poorly understood. Recent cytogenetic studies of GCTs have identified a number of nonrandom abnormalities that affect chromosome 12. The most specific of these was an isochromosome for the short arm [i(12p)], which has been demonstrated in >85% of GCTs, occurring in all described histologic subsets (2) . In a recent cytogenetic analysis of 65 consecutively ascertained GCTs with clonal chromosome abnormalities, we showed that i(12p), monosomy 12 , and deletions in the long arm of chromosome 12 [del(12q) ] occur with frequencies of 86%, 11%, and 20%6, respectively (2) . These data strongly suggested that frequent loss of genetic material on 12q characterizes the development of these tumors.
Specific chromosomal deletions affecting 13q14 in retinoblastoma (3), llpl3 in Wilms tumor (4) , and 5q21 in familial adenomatous polyposis (5) have enabled the identification of a class of genes whose deletion releases the cell from normal regulation of proliferation, the so-called tumor suppressor genes (6) . The location of these genes has been identified at the molecular level by detection of loss of constitutional heterozygosity (LOH) for restriction fragment length polymorphisms (RFLPs) in the target chromosomal regions (7) . LOH, suggesting loss of such suppressor genes, has been demonstrated in a number of solid tumor systems (6) . To define the region of common deletion in GCTs at the molecular level, we compared the genotypes of germ-line and tumor cell RFLPs at eight loci mapped to 12q in 45 patients. These data showed patterns of LOH consistent with the cytogenetic data (i.e., monosomy and deletion of 12q). In addition, high frequencies of LOH identified two sites of candidate tumor suppressor genes, one at 12q13 and the other at 12q22 in these tumors.
The MGF gene product makes up the ligand for the receptor encoded by the KITprotooncogene (reviewed in ref. 8) . We recently mapped MGF to 12q22 (9) , the site of one of the candidate tumor suppressor genes identified in this study. We therefore evaluated three established GCT cell lines and a panel of 24 GCT tumor biopsies for expression of MGF and KIT genes by Northern blot analysis and found deregulated expression of both genes.
MATERIALS AND METHODS
Tumor and Normal Tissues and Cell Lines. The tumor samples and the peripheral blood samples to establish constitutional genotypes were obtained from patients evaluated at The Memorial Sloan-Kettering Cancer Center as described (2) . Tumor biopsy and corresponding peripheral blood samples from 45 patients were used in the LOH study. These tumors were drawn from all histologic subgroups and were composed of 4 seminomas and 41 nonseminomas (11 teratomas, 14 embryonal carcinomas, 3 yolk sac tumors, 1 choriocarcinoma, 1 teratoma with neuroectodermal differentiation, and 11 tumors of mixed histology with various nonseminomatous elements). DNA analysis for LOH was performed on frozen tissue determined to be essentially tumor by examination of cryostat preparations. For RNA analysis, two previously established nonseminomatous cell lines (NT2/D1 and N2102ep), one nonseminomatous cell line recently established by us (240A), and a panel of 24 fresh GCT tumors were utilized. The samples were derived from 10 seminomas, 12 
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. was electrophoresed in 0.8% agarose gels, transferred to nylon membranes, and hybridized with 32P-labeled probes following standard methods. The hybridized filters were read on a Betascope (Betagen) for direct quantitation of signal intensity of allelic bands. Reduction in the signal intensity of an allele by >45% ofthe signal from the germ-line allele (after adjusting for variation in DNA loading) was considered as evidence of LOH. Such losses ranged from 48% to 100%, with the majority exhibiting >60o loss. For Northern blot analysis of KIT and MGF expression, 10 ,ug of total RNA from each tumor was electrophoresed in a 1% agarose/3% formaldehyde gel, transferred to a nylon membrane, and hybridized with [a-32P]dCTP-labeled KIT and MGF cDNA probes.
The probes used in this study consisted ofeight polymorphic (D12S4, D12S6, D12S7, D12S8, D12S12, D12S14, D12S15, and D12S17) and three nonpolymorphic (MGF, IGF1, and IAPP) loci recently mapped by us to specific bands on 12q by using the fluorescence in situ hybridization method (Table 1 ) and a cDNA probe for KIT mapped to 4q (22) . In addition, probes for the JH region of the immunoglobulin heavy-chain gene (IGH) (23) and D14S20 (pMCOC12), both localized on 14q, were used as reference probes for normalization of DNA loading in quantitation of signals from the polymorphic probes used in the LOH assay. The JH probe was a gift from J. Ravetch and the D14S20 probe was obtained from the American Type Culture Collection (ATCC).
RESULTS
Analysis of LOH on 12q. We evaluated 45 tumor DNA samples from 45 patients for allelic losses at eight polymorphic loci mapped to 12q. Except 1 case (no. 185A), all cases were informative for one or more loci (heterozygosity of alleles in the germ line). LOH in tumor DNA compared to germ-line DNA was seen for at least one locus in 22 cases (Fig. 1 ), whereas the remaining tumor DNAs exhibited no loss at any informative loci. One germ-line allele was lost at all the informative loci in three tumors (nos. 143A, 186B, and 239A), suggesting monosomy for 12q ( Fig. 1 ). Although cytogenetic data were not available for these three tumors, two (186B and 239A) were evaluated for chromosome 12 and i(12p) copy number by fluorescence in situ hybridization analysis of interphase cells using a probe for the centromeric a-satellite DNA by a method recently described by us (24) . By this assay, tumor 186B had one to three copies of normal chromosome 12 and one or two copies of i(12p) per cell, whereas tumor 239A had one to six copies of normal chromosome 12 and one to five copies of i(12p) per cell, suggesting that the multiple copies of chromosome 12 resulted from nondisjunctional loss of one parental copy followed by gain of the other (25) . Table 2 summarizes the data on allelic loss in the tumors evaluated, and Fig. 2 illustrates representative Southern blots. Among the probes tested, D12S6, D12S7, and D12S12 showed high (>40%o) frequency losses ( Table 2 ). D12S6 has been mapped to 12q13.3, whereas D12S7 and D12S12 have been mapped to 12q22 (Table 1 ). These data suggested that the distal region of band 12q13 and the region 12q22-qter harbor two candidate tumor suppressor genes (Fig. 1 ). Unfortunately, no polymorphic probes have currently been mapped to the region distal to 12q22, which precluded determination of the distal limit of the deletion by the RFLP assay.
Evidence for Interstitial Deletion in 12q22 in Tumor 143A. As described above, tumor 143A, a seminoma, was one of three tumors in which the LOH data indicated loss of one germ-line copy of 12q, leading to genetic monosomy. RFLP analysis of tumor DNA revealed no signal for D12S7 at 12q22 ( Fig. 3 ). D12S6 at 12ql3.2-13.3 exhibited loss of one allele, whereas the remaining polymorphic loci were uninformative and exhibited signal consistent with a single copy of each of these loci by quantitation of signal intensity (Fig. 3) . To establish the limits of the 12q deletion in this tumor, hybridizations were performed with probes for MGF and D12S12, both of which have also been mapped to 12q22, the closest mapped proximal gene IAPP (12q21-22), and the closest mapped distal gene IGF1 (12q23) ( Table 1 ). These hybridizations showed that MGF was homozygously deleted while IAPP, D12S12, and IGFI were retained, consistent with presence of one copy of chromosome 12. These data, as shown in Fig. 3 , clearly demonstrated an interstitial deletion in the 12q22 region, which included MGF and D12S7 in the single retained chromosome in this tumor. Southern blot analysis of DNA from 89 GCTs using the MGF cDNA probe, however, did not reveal rearrangements or additional cases of homozygous deletions (data not shown).
Expression of MGF and KIT Is Deregulated in GCTs. The above data suggested that loss of function of MGF and/or another gene in the 12q22 region may be one ofthe key events in the development of GCTs. To test for MGF and KIT expression, RNA isolated from 3 GCT cell lines and 24 fresh GCTs was subjected to Northern blot analysis using MGF and KIT cDNA as probes. As shown in Table 3 and Fig. 4 , 1 of the 3 teratocarcinoma cell lines, 1 of the 10 seminomas, and 6 of the 12 nonseminomas showed MGF expression. In contrast, KIT expression was noted in 3 seminomas while none of the teratocarcinoma cell lines and nonseminomatous and combined tumor biopsies expressed KIT mRNA. Only 1 seminoma (no. 157A) expressed both KIT and MGF. Among the 24 GCT tissues studied for MGF expression, 10 were also evaluated for LOH on 12q. MGF mRNA was detected in 5 of these. Of these 10 tumors, 2 were informative for D12S7 localized to 12q22-namely, 155B, which expressed MGF, 0 000 0@e000o 000 0 *0 00000000 00 0 00 * 0000000 000 O *0 0 0000000 000 0 000 000000 000 0 00 0 0000000 000 0000000000 000 0 00 0 00000 0000 000 @00 000 000 @00 000 @00 000 and 235A, which did not express MGF. Both tumors retained germ-line heterozygosity.
DISCUSSION
Male GCTs retain both X and Y chromosomes and hence arise in premeiotic to early meiotic cells (i.e., in spermatogenic cells in stages ofdevelopment from type A spermatogonia to spermatocytes prior to anaphase I of meiosis). Recent molecular studies of mammalian gametogenesis have shown that both spermatogenesis and oogenesis are characterized by unique patterns of expression of a wide array of cellular protooncogenes (26) . Notably, Fos, Jun, and Myc were shown to be specifically expressed at high levels in murine type B spermatogonia (27) , a stage that ushers in a major shift in developmental program (i.e., initiation of meiosis and cessation of further mitotic division by the spermatocyte). Malignant transformation blocks entry or continuation of these cells in meiosis and precipitates a program of unlimited mitotic proliferation.
Our previous cytogenetic data (2) and the molecular data presented here establish i(12p) and del(12q) to be consistently associated with all histologic subsets of GCTs. We have previously shown that i(12p) probably arises from centromeric exchanges in homologous chromosomes (24) ; therefore, it is etiologically unrelated to the deletions in the long arm and possibly represents a second event in the genesis of these tumors. We further showed that, molecularly, the deletions cluster in two regions, 12q13 and 12q22. The losses observed displayed different patterns of minimal region in- volvement-individual tumors exhibited loss of proximal, distal, or both regions (Fig. 1 ). LOH indicating loss of candidate tumor suppressor genes has been documented in a number of specific regions in the human genome in specific tumor types (6) . In the case of chromosome 12, only one previous study indicated LOH, in the region distal to 12q24, in a high proportion of gastric adenocarcinomas (28) . To our knowledge, the deletions detected by us in GCTs have previously not been reported in this or other tumor systems and probably identify sites of candidate tumor suppressor genes specific to GCTs. Of note in this regard is the detection by us ofa homozygous deletion in the 12q22 region in tumor 143A, which offers the opportunity to isolate the deleted gene.
The proximal deleted region in GCTs, 12q13.3, has previously been shown to be associated with frequent transloca- 24.31 o00 00 00000 0-0 00 00000 000 00 000 00 000 00 000 00 (30) . The INT] (WNTJ), GLI, and MDM2 genes have been mapped to the 12ql3-ql4 region (31) (32) (33) . While neither INTl nor GLI were seen to be rearranged in myxoid liposarcomas by Southern blot analysis (34) , pulsed field mapping of 600 kilobases of DNA surrounding the GLI locus showed a specific alteration in the restriction pattern due to methylation differences unique to myxoid liposarcomas (35) . MDM2 has been shown to be amplified and/or overexpressed in soft tissue sarcomas (33) . However, we did not find any genomic alteration ofINTJ, GLII, or MDM2 in male germ cell tumors (data not shown).
Apart from the putative tumor suppressor gene suggested by our results, the only gene of potential relevance to oncogenesis mapped to the distal deleted region, 12q22, as previously noted, is MGF. MGF encodes the ligand for the KIT protooncogene, a tyrosine kinase growth factor receptor that exhibits primary sequence homology with colonystimulating factor type 1 and platelet-derived growth factor receptors and also is homologous to the viral oncogene v-kit (22, 36) . KIT and MGF have been shown to be the structural loci for the murine W and SI loci, respectively; mutations at both loci affect normal development of primordial germ cells, hematopoietic stem cells, and melanocytes (37) (38) (39) (40) (41) . The expression patterns of KIT and MGF in migrating embryonal cells is consistent with a role in homing mechanisms of hematopoietic cells, germ cells, and melanoblasts (42, 43) . In the postnatal murine testis, in situ hybridization studies showed KIT expression from 6 days of age onwards, extend- ing from Al spermatogonia to preleptotene spermatocytes, and in Leydig cells, suggesting a role for this gene in spermatocyte differentiation as well (44) . The expression pattern of MGF in postnatal testes is less well known, although one study by Northern blot analysis suggested expression in Sertoli cells but not in germ cells (45) . With regard to GCTs, although studies of MGF expression have not been reported to date to our knowledge, one recent study observed KIT to be expressed in 80% of seminomas and 7% of nonseminomas (46) . In this study, we noted deregulated and discordant expression of both genes. KIT was expressed in 30%o of the seminomas but in none of the nonseminomas, whereas MGF was expressed in 3% of the seminomas and 50%6 of the nonseminomas. The basis for this pattern of expression currently is unknown. It may represent a deregulated expression of the constitutional phenotype of the precursor cells or de novo expression by the transformed cells. The relationship, if any, between the deregulated expression of MGF and the function of the putative tumor suppressor gene in the 12q22 region also needs to be investigated.
